Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell lines

Journal of Urology

Volumn 163, Issue 3, 2000, Pages 1022-1026

  Blagosklonny, Mikhail V ^a   Dixon, Shannon C ^a   Figg, William D ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Ketoconazole; Paclitaxel; Prostate cancer; Vinblastine

Indexed keywords

ANDROGEN; KETOCONAZOLE; PACLITAXEL; VINBLASTINE;

ANDROGEN BLOOD LEVEL; ARTICLE; CANCER CELL; CELL STRAIN HL 60; DNA SYNTHESIS; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; MICROTUBULE; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0033960594     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67875-5     Document Type: Article

References (26)

1. Mahler, C. and Denis, L.: Management of relapsing disease in prostate cancer. Cancer, 170: 329, 1992
2. Trump, D. L., Havlin, K. H., Messing, E. M., Cummings, K. B., Lange, P. H. and Jordan, V. C.: High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. J Clin Oncol, 7: 1093, 1989
3. Wang, X., Gardner, J. P., Kheir, A., Uskokovic, M. R. and Studzinski, G. P.: Synergistic induction of HL60 cell differentiation by ketoconazole and 1-desoxy analogues of vitamin D3. J Natl Cancer Inst, 89: 1199, 1997
4. Eichenberger, T., Trachtenberg, J., Toor, P. and Keating, A.: Ketaconazole: a possible direct cytotoxic effect on prostate carcinome cells. J Urol, 141: 190, 1989
5. Dixon, S. C., Zalles, A., Giordano, C., Lush, R. M., Venzon, D., Reed, E. and Figg, W. D.: In vitro effect of gallium nitrate when combined with ketoconazole in theprostate cancer cell line PC-3. Cancer Lett, 113: 111, 1997
6. Rowinsky, E. K. and Donehower, R. C.: Paclitaxel (Taxol). N Engl J Med, 332: 1004, 1995
7. Hudes, G. R., Nathan, F. E., Khater, C., Greenberg, R., Gomella, L., Stern, C. and McAleer, C.: Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol, 22 (5 suppl 12): 41, 1995
8. Attivissimo, L. A., Fetten, J. V. and Kreis, W.: Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer. Am J Clin Oncol, 19: 581, 1996
9. Jordan, M. A. and Wilson, L.: Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol, 10: 123, 1998
10. Long, B. H. and Fairchild, C. R.: Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res, 54: 4355, 1994
11. Woods, C. M., Zhu, J., McQueney, P. A., Bollag, D. and Lazarides, E.: Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Medicine, 1: 506, 1995
12. Haldar, S., Jena, N. and Croce, C. M.: Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA, 92: 4507, 1995
13. Blagosklonny, M. V., Giannakakou, P., El-Deiry, W. S., Kingston, D. G. I., Higgs, P. I., Neckers, L. and Fojo, T.: Raf1/bcl2 phosphorylation: a step from microtubule damage to cell death. Cancer Res, 57: 130, 1997
14. Haldar, S., Basu, A. and Croce, C. M.: Bcl2 is the guardian of microtubule integrity. Cancer Res, 57: 229, 1997
15. Figg, W. D., Walls, R. G., Cooper, M. R., Thibault, A., Sartor, O., McCall, N. A., Myers, C. E. and Samid, D.: In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate. Anticancer Drugs, 5: 336, 1994
16. Borner, M. M., Myers, C. E., Sartor, O., Sei, Y., Toko, T., Trepel, J. B. and Schneider, E.: Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res, 55: 2122, 1995
17. Blagosklonny, M. V., Chuman, Y., Bergan, R. C. and Fojo, T.: Mitogen activated protein kinase pathway is dispensible for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells. Leukemia, 13: 1028, 1999
18. Daneshmend, T. K. and Warnock, D. W.: Clinical pharmacokinetics of ketoconazole. Clin Pharm, 14: 13, 1988
19. Carroll, A. G., Voeller, H. J., Sugars, L. and Gelmann, E. P.: p53 oncogene mutations in three human prostate cancer cell lines. Prostate, 23: 123, 1993
20. Torres, K. and Horwitz, S. B.: Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res, 58: 3620, 1998
21. Giannakakou, P., Villalba, L., Li, H., Poruchynsky, M. and Fojo, T.: Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule. Int J Cancer, 75: 57, 1998
22. Ellerhorst, J. A., Tu, S. M., Amato, R. J., Finn, L., Millikan, R. E., Pagliaro, L. C., Jackson, A. and Logothetis, C. J.: Phase II trial of alterating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res, 3: 2371, 1997
23. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J. J. and Kohn, K. W.: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute Anticancer Drug Screen and correlations with growth-inhibitory potency of 123 anticancer agents. Cancer Res, 57: 4285, 1997
24. Stapleton, A. M. F., Timme, T. L., Gousse, A. E., Li, Q. F., Tobon, A. A., Kattan, M. W., Slawin, K. M., Wheeler, T. M., Scardino, P. T. and Thompson, T. C.: Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res, 3: 1389, 1997
25. de Souza, P. L., Castillo, M. and Myers, C. E.: Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine. Br J Cancer, 75: 1593, 1997
26. Danesi, R., Figg, W. D., Reed, E. and Myers, C. E.: Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. Mol Pharmacol, 47: 1106, 1995